Meropenem plus Ertapenem and Ceftazidime–Avibactam plus Aztreonam for the Treatment of Ventilator Associated Pneumonia Caused by Pan-Drug Resistant Klebsiella pneumonia

Konstantinos Mantzarlis,Efstratios Manoulakas,Kyriaki Parisi,Evaggelia Sdroulia,Nikolaos Zapaniotis,Vassiliki Tsolaki,Epaminondas Zakynthinos,Demosthenes Makris

DOI: https://doi.org/10.3390/antibiotics13020141

2024-02-01

Antibiotics

Abstract:Introduction: Gram-negative bacteria (GNB) account for about 70% of infections in the intensive care unit (ICU) setting and are associated with significant morbidity and mortality. In recent years, pan-drug resistant (PDR) strains, strains that are not susceptible to any antibiotic, have been emerged and new treatment strategies are required. Results: Fifty eligible patients were recruited in the three groups. A statistically significant reduction in the Sequential Organ Failure Assessment (SOFA) score was observed in the control group on day 4 in comparison to day 0 of VAP (p = 0.005). The Clinical Pulmonary Infection Score (CPIS) was also reduced on day 4 (p = 0.0016) and day 7 in comparison to day 0 (p = 0.001). Patients that received combination therapy, CAZ–AVI + ATM and DCT, presented with a lower SOFA score and CPIS on day 7 in comparison to day 0 (p = 0.0288 and p = 0.037, respectively). No differences in the ΔSOFA score and ΔCPIS were found between the groups. The control group presented with a significantly lower ICU stay and duration of mechanical ventilation (p = 0.03 and p = 0.02, respectively). There was no difference in mortality. Materials and methods: This is a retrospective analysis. This study was conducted in a mixed ICU in the University Hospital of Larissa, Thessaly, Greece during a three-year period (2020-2022). Patients suffering from ventilator associated pneumonia (VAP) due to carbapenem-resistant K. pneumonia (CR-KP) were divided in three different groups: the first one was treated using ceftazidime–avibactam plus aztreonam (CAZ–AVI + ATM group), the second was treated using double carbapenems (DCT group), and the last one (control group) received appropriate therapy since the strain was susceptible in vitro to at least to one antibiotic. Conclusions: Treatment with CAZ–AVI +ATM or DCT may offer a clinical benefit in patients suffering with infections due to PDR K. pneumoniae. Larger studies are required to confirm our findings.

pharmacology & pharmacy,infectious diseases

What problem does this paper attempt to address?

The paper primarily explores the efficacy of two antibiotic combination therapies in treating Ventilator Associated Pneumonia (VAP) caused by pan-drug resistant (PDR) Klebsiella pneumoniae.

The core issue addressed by the paper is the lack of effective treatment methods for VAP caused by PDR Klebsiella pneumoniae. Specifically, the study compares the effects of the following two antibiotic combination therapies:
1. Ceftazidime–Avibactam (CAZ–AVI) combined with Aztreonam (ATM);
2. Double Carbapenem Therapy (DCT), which is Meropenem combined with Ertapenem.

The study results indicate that both antibiotic combination therapies can improve clinical indicators to some extent, such as the Sequential Organ Failure Assessment (SOFA) score and the Clinical Pulmonary Infection Score (CPIS). However, compared to the control group (patients receiving at least one in vitro sensitive antibiotic treatment), the effects of these combination therapies are slightly inferior, as evidenced by longer mechanical ventilation time and Intensive Care Unit (ICU) stay, although there was no significant difference in mortality rates between the groups.

Overall, the paper provides preliminary evidence suggesting that these two antibiotic combination therapies may be beneficial for treating VAP caused by PDR Klebsiella pneumoniae, but larger-scale studies are needed to further confirm these findings.